Navigation Links
InnoPharma Completes $15 Million Series A Financing
Date:12/1/2011

PISCATAWAY, N.J., Dec. 1, 2011 /PRNewswire/ -- InnoPharma, Inc., a developer of sterile generic and specialty pharmaceutical products, announced that it has completed a $15 million Series A round of private financing. This financing was led by Thomas, McNerney & Partners.

"We are very pleased that InnoPharma's aggressive and well-managed growth over the last few years has allowed us to attract an outstanding investor, whose expertise and professional network will add tremendous value to InnoPharma," stated Navneet Puri, Ph.D., Founder, President, and Chief Executive Officer of InnoPharma. "The funds raised in this financing will allow us to accelerate the development of our product pipeline and also maximize the value that we offer to our customers and end users."

As a result of the financing, two new members have joined InnoPharma's board of directors: Alex Zisson and James Thomas, both partners at Thomas, McNerney & Partners.  The new board of directors will also include Navneet Puri, Raman Kapur, the former CEO of Warrick Pharmaceuticals, and Peter Werth, the CEO of ChemWerth.

"We're very excited to be partnering with InnoPharma.  The company's track record of FDA filings, approvals and partnerships is very impressive, and the additional resources will help InnoPharma maximize the true potential of its pipeline," said Alex Zisson.

Ledgemont Capital Group, LLC, served as the company's placement agent, and Lowenstein Sandler PC served as the company's legal counsel. Thomas, McNerney & Partners was represented by Goodwin Procter LLP.

About INNOPHARMA:

INNOPHARMA is a developer of sterile generic and specialty pharmaceutical products.  Through a business model of internal product development and commercialization licensure, INNOPHARMA has a comprehensive infrastructure for development of injectable and ophthalmic pharmaceutical products at its New Jersey facilities.  INNOPHARMA
'/>"/>

SOURCE INNOPHARMA LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Biocartis Completes EUR 71 Million (USD 100 Million) Series C Fund Raising
2. Agendia Successfully Completes Bi-Annual FDA Inspection
3. HeartWare Completes GLP Studies of Next Generation MVAD® Pump; Data Presented Today at ISRBP Congress
4. Enterologics Completes Acquisition of BioBalance Corp and Probiotic Product From New York Health Care, Inc
5. TWi Biotechnology Successfully Completes Patient Recruitment for Phase IIb Trial of AC-201 for the Treatment of Type II Diabetes
6. Kuros Completes Patient Recruitment in a Phase IIb Clinical Trial With KUR-211 for Diabetic Foot Ulcers
7. AMPAC Fine Chemicals Completes Contract Manufacturing Agreement for Smallpox Countermeasure API
8. Peloton Therapeutics Completes $18 Million Series A Financing
9. Sinapis Pharma Completes Phase I Trial
10. MiMedx Group Completes $5,000,000 Private Placement
11. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... , Dec. 15, 2014 Organovo Holdings, ... company focused on delivering breakthrough 3D bioprinting technology,  ... and collaborators of its exVive3D TM Human ... available in full commercial release on November 18, ... resulting in several awards for innovation. ...
(Date:12/13/2014)... , Dec. 12, 2014 /CNW/ - MaRS and Virgin Unite ... that they have joined forces to support Canadian entrepreneurs tackling ... Virgin Group Founder was at the MaRS Centre to announce ... national impact venture fund. This fund has $1 million in ... Vancouver -based Mindset Social Innovation Foundation, founded by ...
(Date:12/13/2014)... (PRWEB) December 13, 2014 According to ... million people between now and 2030." If a population ... the seventh most populous state in the country. , ... gathering at the Future of North Carolina Forum on ... Do we have the necessary infrastructure in place? Enough ...
(Date:12/13/2014)... SAN ANTONIO , Dec. 12, 2014 /PRNewswire/ ... presentation of data at the San Antonio Breast Cancer ... epoetin alfa plus best supportive care (BSC) versus BSC ... breast cancer receiving standard chemotherapy. This non-inferiority trial did ... out a 15 percent or greater increase in the ...
Breaking Biology Technology:Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3North Carolina Chamber of Commerce: Asking Questions & Gathering Answers with a Futurist 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 4Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 5Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 6Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 7Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 8Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 9Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 10Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 11Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 12
... YOKOHAMA, Japan, Aug. 27 MaxCyte,Inc. and ... the signing of an,exclusive license, development and ... system to support clinical studies and,commercialization of ... of the agreement, MaxCyte will provide the ...
... RESEARCH TRIANGLE PARK, N.C., Aug. 27 ... Pharmaceuticals, Inc., a,clinical-stage biopharmaceutical company specializing in ... private placement of C$26 million,(US$25 million) in ... investment by NovaQuest, the strategic partnering group,of ...
... Aug. 27 /Xinhua-PRNewswire-FirstCall/ -- China Technology,Development Group Corporation ... appointment of Charlene Hua as the Company,s new ... a board,resolution passed on the same date. This ... the Company. As Chief Financial Officer, Ms. ...
Cached Biology Technology:Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan 2Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan 3NovaQuest Advances 'Virtual Development' Model With Strategic Investment in TOPIGEN Pharmaceuticals 2China Technology Announces New Chief Financial Officer 2China Technology Announces New Chief Financial Officer 3
(Date:12/17/2014)...  HITLAB SM announced today its completion ... confirm its adherence to current U.S. Food and ... to conduct regulated smart device and smart phone ... safety and research quality. "HITLAB is ... delivery with innovative technology," said Laura Pugliese ...
(Date:12/17/2014)... Dec. 16, 2014  Automation is fundamentally transforming ... evident than at international borders. Over the past ... have allowed veteran travelers to self process through ... (APC) Kiosks at an increasing number of airports, ... According to Maxine Most , ...
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition ... report to their offering. ... the adoption of multimodal biometric systems. Multimodal biometric ... individual for verification and identification purposes. This helps ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... Science Brief presents a roadmap for marine biodiversity science ... provides 95% of the habitable space on Earth and ... health of the oceans and their productive ecosystems which ... life is under significant threat from climate change and ...
... causing alarm among global public health authorities after it killed ... is now linked to two other cases of disease is ... found in bats, according to a genetic analysis to be ... the American Society for Microbiology, on November 20. Researchers studied ...
... including Carnegie Museum of Natural History scientist John ... Necrolestes patagonensis , whose name translates into grave ... This much-debated fossil mammal from South America has ... years. Scientific perseverance, a recent fossil discovery, and ...
Cached Biology News:Europe must not lose momentum in marine biodiversity research 2New coronavirus related to viruses from bats 2New coronavirus related to viruses from bats 3After 121 years, identification of 'grave robber' fossil solves a paleontological enigma 2After 121 years, identification of 'grave robber' fossil solves a paleontological enigma 3After 121 years, identification of 'grave robber' fossil solves a paleontological enigma 4After 121 years, identification of 'grave robber' fossil solves a paleontological enigma 5